<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35700157</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].</ArticleTitle><Pagination><StartPage>e0258614</StartPage><MedlinePgn>e0258614</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0258614</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0258614</ELocationID><Abstract><AbstractText Label="BACKGROUND">Edaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19). One of the Study 19 inclusion criteria was forced vital capacity (FVC) &#x2265;80% of predicted (&#x2265;80%p). Therefore, the study provided no information on edaravone efficacy in subjects with FVC &lt;80%p. In Study 19, 24-week, double-blind treatment was followed by open-label treatment where all subjects received edaravone. At 24 weeks, some subjects had FVC &lt;80%p (FVC24 &lt;80%p). This allowed for post-hoc assessment of the effects of edaravone in subgroups of subjects with FVC24 &#x2265;80%p vs &lt;80%p.</AbstractText><AbstractText Label="OBJECTIVE">To address the question of the efficacy of edaravone in ALS patients with FVC &lt;80%p.</AbstractText><AbstractText Label="METHODS">Post-hoc analysis of Study 19 comparing edaravone efficacy at week 48 in subjects with FVC24 &#x2265;80%p vs &lt;80%p.</AbstractText><AbstractText Label="RESULTS">With edaravone treatment, subjects in both the FVC24 &#x2265;80%p and the FVC24 &lt;80%p subgroups experienced a reduction in ALS Functional Rating Scale-Revised (ALSFRS-R) score loss vs placebo subjects through week 48. For the FVC24 &#x2265;80%p subgroup, the changes in ALSFRS-R scores from baseline to week 48 were -7.63 for edaravone-edaravone vs -9.69 for placebo-edaravone, a difference of 2.05 (P = .034; 95% CI: 0.16, 3.94). For the FVC24 &lt;80%p subgroup, the changes in ALSFRS-R scores from baseline to week 48 were -10.26 for edaravone-edaravone vs -15.20 for placebo-edaravone, a difference of 4.94 (P = .0038; 95% CI: 1.64, 8.25). Linear regression analysis indicated that, in the FVC24 &lt;80%p subgroup, there was a notable change in the slope of the ALSFRS-R score-vs-time graph after the start of edaravone treatment.</AbstractText><AbstractText Label="CONCLUSION">ALS subjects in the Study 19 placebo arm had a slowing in disease progression, even when edaravone was added with an FVC of &lt;80%p prior to starting edaravone. A randomized, placebo-controlled study is needed to validate these post-hoc findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Benjamin Rix</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-1914-5061</Identifier><AffiliationInfo><Affiliation>Atrium Health Neurosciences Institute, Carolinas Medical Center, University of North Carolina School of Medicine-Charlotte Campus, Charlotte, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heiman-Patterson</LastName><ForeName>Terry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiedau-Pazos</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shawn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma Development America, Jersey City, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Princeton Pharmatech, West Windsor, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apple</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical><Chemical><RegistryNumber>T3CHA1B51H</RegistryNumber><NameOfSubstance UI="D000983">Antipyrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000983" MajorTopicYN="N">Antipyrine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors of this paper have read the journal&#x2019;s policy and have the following competing interests: SA and SL are paid employees of MTPA. Authors BRB, THP, and MWP are consultants for MTPA, but did not receive any compensation for their work on this study or for writing this manuscript. JZ is a paid employee of Princeton Pharmatech. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>14</Day><Hour>13</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35700157</ArticleId><ArticleId IdType="pmc">PMC9197041</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0258614</ArticleId><ArticleId IdType="pii">PONE-D-19-30686</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;72. doi: 10.1056/NEJMra1603471 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy&#x2014;a roundtable discussion. Am J Manag Care. 2018;24(9 suppl):S175&#x2013;S86. .</Citation><ArticleIdList><ArticleId IdType="pubmed">29693363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, et al.. Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5&#x2013;6):321&#x2013;30. doi: 10.1080/21678421.2018.1452945 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1452945</ArticleId><ArticleId IdType="pubmed">29566571</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest. 2019;155(2):401&#x2013;8. doi: 10.1016/j.chest.2018.06.035 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, et al.. Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5&#x2013;6):331&#x2013;41. doi: 10.1080/21678421.2018.1457058 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1457058</ArticleId><ArticleId IdType="pubmed">29661084</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M. Correlation between Forced Vital Capacity and Slow Vital Capacity for the assessment of respiratory involvement in Amyotrophic Lateral Sclerosis: a prospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1&#x2013;2):86&#x2013;91. doi: 10.1080/21678421.2016.1249486 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1249486</ArticleId><ArticleId IdType="pubmed">27915482</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77(3):390&#x2013;2. doi: 10.1136/jnnp.2005.072660 ; PubMed Central PMCID: PMC2077717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.072660</ArticleId><ArticleId IdType="pmc">PMC2077717</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId></ArticleIdList></Reference><Reference><Citation>Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology. 1998;50(1):66&#x2013;72. doi: 10.1212/wnl.50.1.66 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.50.1.66</ArticleId><ArticleId IdType="pubmed">9443459</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, Rothstein J, Clawson L, Diette GB, Wiener CM. Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(1):5&#x2013;13. doi: 10.1080/146608202317576480 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608202317576480</ArticleId><ArticleId IdType="pubmed">12061943</ArticleId></ArticleIdList></Reference><Reference><Citation>Radicava&#xae; (edaravone injection) [package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation; August 2018.</Citation></Reference><Reference><Citation>Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;12. doi: 10.1016/S1474-4422(17)30115-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al.. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):610&#x2013;7. doi: 10.3109/21678421.2014.959024 ; PubMed Central PMCID: PMC4266079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo JM, Hubble J, Apple S, Takei K, Tsuda K, Liu S, et al.. Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5&#x2013;6):421&#x2013;31. doi: 10.1080/21678421.2019.1599955 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1599955</ArticleId><ArticleId IdType="pubmed">30982356</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis NJ. What can we learn from the edaravone development program for ALS? Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):98&#x2013;103. doi: 10.1080/21678421.2017.1361446 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361446</ArticleId><ArticleId IdType="pubmed">28872911</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):5&#x2013;10. doi: 10.1080/21678421.2017.1353101 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1353101</ArticleId><ArticleId IdType="pubmed">28872907</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun SR, Rosenfeld J. Edaravone in amyotrophic lateral sclerosis&#x2014;lessons from the clinical development program and the importance of a strategic clinical trial design. US Neurology. 2018;14(1):47&#x2013;53.</Citation></Reference><Reference><Citation>Takei K, Tsuda K, Takahashi F, Palumbo J. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):64&#x2013;70. doi: 10.1080/21678421.2017.1365372 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1365372</ArticleId><ArticleId IdType="pubmed">28872916</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone ALS 19 Study Group. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):55&#x2013;63. doi: 10.1080/21678421.2017.1364269 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1364269</ArticleId><ArticleId IdType="pubmed">28872920</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):49&#x2013;54. doi: 10.1080/21678421.2017.1361443 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361443</ArticleId><ArticleId IdType="pubmed">28872913</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Drug Evaluation and Research (CDER). Office director memo for application number 209176Orig1s0002017 June 18, 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000ODMemo.pdf.</Citation></Reference><Reference><Citation>Vu M, Tortorice K, Zacher J, Dong D, Hur K, Zhang R, et al.. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System. JAMA Netw Open. 2020;3(10):e2014645. Epub 2020/10/06. doi: 10.1001/jamanetworkopen.2020.14645 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.14645</ArticleId><ArticleId IdType="pmc">PMC7536587</ArticleId><ArticleId IdType="pubmed">33017028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz JF, Khan SA, Salem A, Lin Z, Iqbal Z, Jahan N. Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug. Cureus. 2020;12(10):e10818. doi: 10.7759/cureus.10818 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.10818</ArticleId><ArticleId IdType="pmc">PMC7645306</ArticleId><ArticleId IdType="pubmed">33173626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Biguzzi S, Guidi C, Sette E, Terlizzi E, Ravasio A, et al.. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy. Neurol Sci. 2015;36(12):2243&#x2013;52. doi: 10.1007/s10072-015-2343-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-015-2343-6</ArticleId><ArticleId IdType="pubmed">26205535</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr. 2018;62(1):20&#x2013;38. doi: 10.3164/jcbn.17-62 ; PubMed Central PMCID: PMC5773834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.17-62</ArticleId><ArticleId IdType="pmc">PMC5773834</ArticleId><ArticleId IdType="pubmed">29371752</ArticleId></ArticleIdList></Reference><Reference><Citation>Cova E, Bongioanni P, Cereda C, Metelli MR, Salvaneschi L, Bernuzzi S, et al.. Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. Neurochem Int. 2010;56(5):687&#x2013;93. doi: 10.1016/j.neuint.2010.02.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2010.02.004</ArticleId><ArticleId IdType="pubmed">20152873</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiduschat N, Mao X, Hupf J, Armstrong N, Kang G, Lange DJ, et al.. Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci Lett. 2014;570:102&#x2013;7. Epub 2014/04/29. doi: 10.1016/j.neulet.2014.04.020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.04.020</ArticleId><ArticleId IdType="pubmed">24769125</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E, Salvador R, Lopez-Blanch R, Jihad-Jebbar A, Valles SL, Estrela JM. Oxidative Stress, Neuroinflammation and Mitochondria in the Pathophysiology of Amyotrophic Lateral Sclerosis. Antioxidants (Basel). 2020;9(9). Epub 2020/09/26. doi: 10.3390/antiox9090901 ; PubMed Central PMCID: PMC7555310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9090901</ArticleId><ArticleId IdType="pmc">PMC7555310</ArticleId><ArticleId IdType="pubmed">32971909</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al.. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416&#x2013;22. doi: 10.1016/S1474-4422(18)30054-1 ; PubMed Central PMCID: PMC5899963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibold H, Zeileis A, Hothorn T. Model-Based Recursive Partitioning for Subgroup Analyses. Int J Biostat. 2016;12(1):45&#x2013;63. Epub 2016/05/27. doi: 10.1515/ijb-2015-0032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/ijb-2015-0032</ArticleId><ArticleId IdType="pubmed">27227717</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibold H, Zeileis A, Hothorn T. Individual treatment effect prediction for amyotrophic lateral sclerosis patients. Stat Methods Med Res. 2018;27(10):3104&#x2013;25. Epub 2018/01/05. doi: 10.1177/0962280217693034 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280217693034</ArticleId><ArticleId IdType="pubmed">29298618</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD, Bettica P, Brooks BR, Pioro EP. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020:1&#x2013;10. Epub 2020/06/24. doi: 10.1080/21678421.2020.1771734 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Sanjak M. Disease-modifying drug therapies. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5 Suppl 1:68&#x2013;75. Epub 2004/10/30. doi: 10.1080/17434470410019898 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17434470410019898</ArticleId><ArticleId IdType="pubmed">15512878</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>